Skip to content

Welcome to Discover Pharma! Today is : October 7, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

oral infigratinib

  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    BridgeBio gets FDA Priority Review for oral infigratinib in achondroplasia

    BridgeBio has secured FDA Priority Review for its oral infigratinib [...]

    October 7, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Andelyn to manufacture FDA-approved Fayuvi gene therapy for Sanfilippo syndrome
    Categories: Advanced Therapies, Biotech & Pharma Business, Central Nervous System, Clinical & Regulatory, Manufacturing & Supply Chain, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Ariadne Bio launches with Parkinson’s apathy drug candidate
    Categories: Biotech & Pharma Business, Central Nervous System, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • MaaT Pharma to advance Phase 3 trial after EMA rejects MaaT013 application
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top